Overview

Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Interferon alfa-2b may interfere with the growth of cancer cells. PURPOSE: Randomized phase III trial to study the effectiveness of interferon alfa-2b in treating patients who have melanoma with early lymph node metastasis.
Phase:
Phase 3
Details
Lead Sponsor:
University of Alabama at Birmingham
Collaborator:
National Cancer Institute (NCI)
Treatments:
Interferon-alpha
Interferons